Profile data is unavailable for this security.
About the company
Hemas Holdings PLC is a Sri Lanka-based holding company, which is engaged in investment activities and provides advisory services to other companies in the Hemas Group. The Company’s segments include Consumer Brands, Healthcare, Mobility and Other. Consumer Brands segment offers a range of products for babies and adults in hair care, skin care, toiletries, fragrances, and oral care under the brands Kumarika, Clogard and Velvet, among others. Its brand Atlas Axillia provides school stationery and notebooks, pens, pencils, and color products. Healthcare segment is engaged in healthcare services which include pharmaceutical distribution and hospitals services under its business Hemas Hospitals, Hemas Pharmaceuticals and Morison. Mobility segment is engaged in haulage, container yard operations, warehousing, automotive logistics, transportation of project, and over-dimensional cargo services. The Company has its operations in Sri Lanka, Bangladesh, West Bengal, and Myanmar.
- Revenue in LKR (TTM)122.38bn
- Net income in LKR5.59bn
- Incorporated1948
- Employees5.38k
- LocationHemas Holdings PLCNo 75, Braybrooke Place, Colombo 02COLOMBO 01Sri LankaLKA
- Phone+94 114731713
- Fax+94 112332889
- Websitehttps://www.hemas.com/
Mergers & acquisitions
| Acquired company | HHL.N0000:CSE since announced | Transaction value |
|---|---|---|
| Atlas Axillia Co (Pvt) Ltd | 23.28% | 11.41m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111 Inc - ADR | 616.44bn | -16.19bn | 27.57bn | 1.66k | -- | -- | -- | 0.0447 | -0.6413 | -0.6413 | 24.50 | -0.9598 | 4.56 | 9.66 | 29.15 | -- | -10.77 | -17.09 | -- | -178.25 | 5.68 | 5.36 | -2.36 | -4.37 | 0.5457 | -32.73 | 0.5781 | -- | 10.59 | 52.95 | 5.80 | -- | -- | -- |
| Pharmaniaga Berhad | 213.01bn | -4.85bn | 31.11bn | 3.78k | -- | -- | -- | 0.1461 | -0.0572 | -0.0572 | 2.55 | -0.2056 | 1.82 | 4.59 | 9.57 | -- | -4.06 | -6.88 | -- | -38.45 | 9.04 | 6.64 | -2.23 | -3.66 | 0.2762 | 1.37 | 1.29 | -- | -3.02 | 7.38 | 87.25 | -- | 23.35 | -- |
| Sopharma Trading AD | 272.98bn | 4.88bn | 31.73bn | 2.62k | 6.51 | 1.58 | 3.15 | 0.1162 | 0.8761 | 0.8761 | 49.05 | 3.62 | 2.77 | 0.1598 | 7.91 | 642,617.00 | 4.95 | 2.43 | 14.93 | 7.97 | 98.03 | 98.08 | 1.79 | 1.02 | 0.6065 | 187.70 | 0.6132 | -- | 13.02 | 13.26 | 230.70 | 28.57 | 3.70 | -- |
| EQL Pharma AB | 6.76bn | 607.44m | 35.09bn | 19.00 | 59.46 | 7.39 | -- | 5.19 | 0.74 | 0.74 | 8.21 | 5.95 | 0.8025 | 1.79 | 3.56 | 13,687,060.00 | 7.21 | 8.77 | 11.96 | 14.23 | 45.33 | 39.60 | 8.98 | 7.63 | 0.5617 | 13.71 | 0.3616 | -- | -36.57 | -- | -1.99 | -- | -- | -- |
| Profarma Distribuidora de Produts Frm SA | 505.10bn | 4.11bn | 39.04bn | 7.08k | 9.37 | 0.5284 | 2.96 | 0.0773 | 0.5742 | 0.5742 | 70.64 | 10.18 | 1.86 | 5.33 | 7.77 | -- | 1.67 | 1.64 | 3.63 | 3.40 | 14.92 | 14.61 | 0.8989 | 0.9519 | 0.8223 | 1.81 | 0.4263 | -- | 10.82 | 15.19 | -12.95 | -- | 41.08 | -- |
| Charmacy Pharmaceutical Co Ltd | 181.61bn | 2.12bn | 42.36bn | 831.00 | 20.01 | 1.72 | 26.87 | 0.2333 | 0.5149 | 0.5149 | 44.16 | 5.99 | 1.44 | 6.05 | 4.88 | 5,738,961.00 | 1.68 | 1.79 | 8.28 | 7.99 | 6.35 | 6.11 | 1.17 | 1.24 | 0.7775 | 2.71 | 0.5111 | 37.10 | 5.47 | 2.27 | -43.25 | 2.48 | -- | 0.0193 |
| Hemas Holdings PLC | 122.38bn | 5.59bn | 49.52bn | 5.38k | 8.86 | 1.21 | 6.41 | 0.4047 | 9.36 | 9.36 | 204.88 | 68.56 | 1.28 | 3.13 | 4.20 | 22,747,760.00 | 6.28 | 5.53 | 12.69 | 9.99 | 29.62 | 29.98 | 4.93 | 4.99 | 0.9711 | 3.28 | 0.3388 | 41.15 | 44.54 | 17.51 | 0.4779 | 9.70 | -9.33 | 5.66 |
| Salus Ljubljana dd | 157.45bn | 4.16bn | 66.61bn | 144.00 | 15.86 | 2.81 | 11.92 | 0.4231 | 125.46 | 125.46 | 4,748.71 | 707.47 | 2.88 | 9.88 | 8.30 | -- | 7.62 | 6.51 | 15.82 | 13.29 | 10.86 | 8.66 | 2.64 | 2.37 | 0.8977 | 121.66 | 0.1817 | 60.88 | 8.16 | 16.33 | 0.687 | 27.73 | 30.81 | 14.87 |
| Holder | Shares | % Held |
|---|---|---|
| Kopernik Global Investors LLCas of 29 Feb 2024 | 30.15m | 5.05% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 18.32m | 3.07% |
| Tundra Fonder ABas of 30 Jun 2023 | 7.00m | 1.17% |
| Holberg Fondsforvaltning ASas of 31 Mar 2024 | 4.76m | 0.80% |
| Tiff Advisory Services LLCas of 31 Dec 2023 | 1.34m | 0.22% |
| Parametric Portfolio Associates LLCas of 29 Feb 2024 | 404.76k | 0.07% |
